Results 231 to 240 of about 238,995 (362)

Myocardial Damage and Inflammatory Response After Cardiac Surgical Revascularization on Beating and Arrested Heart. [PDF]

open access: yesBraz J Cardiovasc Surg
Bosnjak A   +5 more
europepmc   +1 more source

Risk factors for silent cerebral infarction in immune‐mediated thrombotic thrombocytopenic survivors

open access: yesBritish Journal of Haematology, EarlyView.
Summary Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) survivors are predisposed to silent cerebral infarctions (SCI) defined as radiological evidence of brain ischaemia without focal symptoms. This study examined risk factors associated with SCI burden in iTTP survivors during remission.
Binish Javed   +13 more
wiley   +1 more source

Variation of pre- and post-race cardiac troponin concentrations in Thoroughbred and Arabian racehorses [PDF]

open access: diamond
Nilgün Paksoy   +3 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

A quad‐cistronic fluorescent biosensor system for real‐time detection of subcellular Ca2+ signals

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose The calcium ion (Ca2+) is a versatile cellular messenger regulating a variety of biological processes. Compounds modulating subcellular Ca2+ signals hold substantial pharmacological potential. Advances in fluorescent biosensors have revolutionised Ca2+ imaging.
Anna Lischnig   +7 more
wiley   +1 more source

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev   +36 more
wiley   +1 more source

Examining the Severity and Consequences of Patients Admitted With Acute Chest Pain via the Acute Physiology and Chronic Health Evaluation II Score and the Relevance of Adding High-Sensitivity Troponin Testing. [PDF]

open access: yesCureus
Farag Y   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy